Diabetes (type 1 and 2) - inhaled insulin
Inhaled insulin for the treatment of type 1 and type 2 diabetes
Summary
In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete.
Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications.
25 January 2008
Guidance documents
Implementing this guidance
We will consult on our review plans for this guidance in September 2009
About this guidance
Technology appraisals TA113
Issued: December 2006